XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
  Drug Delivery
  Nanotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Biotechnology Channel
subscribe to Biotechnology newsletter

Latest Research : Biotechnology

   DISCUSS   |   EMAIL   |   PRINT
Biotech failed to meet promises
Oct 14, 2005 - 9:43:00 PM, Reviewed by: Dr.

The promises of biotechnology substances to be more effective and less toxic than conventional drugs have been only partially fulfilled, they add. Many of the substances produced so far are analogues of existing drugs and have contributed little to innovation in medicine.

 
Promises of cheaper and better drugs using biotechnologies have not been met, say researchers in this week�s BMJ. They assessed biotech products approved by the European Medicine Evaluation Agency between 1995 and 2003.

Of 61 products licensed for therapeutic use, only 15 were for diseases without effective treatment, more effective than existing treatment, or active in patients resistant to current treatment.

A further 22 offered limited advantages over existing products, and 24 were copycat drugs, many of which have failed to offer new options for patients and provide no cost advantage, say the authors.

Furthermore, evaluation of these substances was not always based on rigorous methodological criteria, suggesting that commercial priorities come before the sound development of drugs in the interest of patients.

The promises of biotechnology substances to be more effective and less toxic than conventional drugs have been only partially fulfilled, they add. Many of the substances produced so far are analogues of existing drugs and have contributed little to innovation in medicine.

Nevertheless, biotechnology has made it possible to make available drugs that would otherwise be impossible to obtain in large amounts or research tools that are useful for discovering new drugs. �Let us hope that in future biotechnology will better live up to its promises.�
 

- British Medical Journal Issue Dated 15 October 2005 (Vol 331, No 7521)
 

Read full text article on http://bmj.com

 
Subscribe to Biotechnology Newsletter
E-mail Address:

 



Related Biotechnology News

Gold Nanoparticle Molecular Ruler to Measure Smallest of Life�s Phenomena
Tiny inhaled particles take easy route from nose to brain
DNA Amplification and Detection Made Simple
Solitons Could Power Artificial Muscles
Nanoparticles could deliver multi-drug therapy to tumors
Nanotechnology can identify disease at early cellular level
Light-sensitive particles change chemistry at the flick of a switch
DNA Fragments for Making Tomatoes Taste Better Identified
'Custom' nanoparticles could improve cancer diagnosis and treatment
Human albumin from tobacco plants


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us